ABSTRACT-The present study characterizes the neurochemical profile of the newly synthesized compound 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HC1 (MKC-242). In in vitro experiments, MKC-242 had high affinity for serotonin,A (5-HTIA) receptors (K;: 0.35 nM) and moderate affinity for a,-adrenoceptors (K,: 21 nM), whereas it had no appreciable affinity for any other neurotransmitter recognition sites studied and 5-HT transporter. MKC-242 (0.3-3.0 mg/kg, s.c.; 1-10 mg/kg, p.o.) caused presynaptic 5-HT,A-receptor-mediated responses (decreases in 5-HT turnover and 5-HT release) and postsynaptic 5-HT,A-receptor-mediated responses (hypothermia, an increase in serum corticosterone level and 5-HT,A behavioral syndrome). The effects of MKC-242 on decarboxylase inhibitor-induced 5-hydroxytryptophan accumulation and rectal temperature were blocked by the 5-HT,A-receptor antagonist N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide.
Serotonin (5-HT) receptors are heterogeneous, being classified into the distinct main classes from 5-HT, to 5-HT7 receptor families, and the 5-HT, family consists of several receptor subtypes (1-3). 5-HT,A receptors of these receptor subtypes have been studied most intensively because of the availability of the 5-HT,A-receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (4, 5) and the proposed clinical utilities of the 5-HT,A-receptor agonists azapirones (buspirone, gepirone, ipsapirone and tandospirone) for treatment of anxiety and depression (6, 7) . However, these 5-HT,A-receptor agonists act not only at 5-HT,A receptors but also at other sites; for example, buspirone, gepirone and ipsapirone markedly increase the turnover rate of dopamine (DA) in rat brain in a 5-HT,A-receptor-independent mechanism (8) . In addition, a metabolite of azapirones, 1-(2-pyrimidyl)piperazine, exhibits potent a2-adrenoceptor antagonistic properties (9, 10) and exerts opposite effects to those associated with the stimulation of 5-HT,A receptors (11) . These findings argue against the hypothesis that 5-HT,A receptors may be a molecular target for the nonbenzodiazepine anxiolytics.
5-HT,A receptors are localized presynaptically on serotonergic perikarya in raphe nuclei and postsynaptically on non-serotonergic neurons in several brain regions (12, 13) . The activation of the former receptors causes decreases in 5-HT synthesis and release, while that of the latter receptors causes induction of corticosterone secretion, hypothermia and behavioral effects (14, 15) . The inhibition by 5-HT1A-receptor ligands of forskolin-stimulated adenylate cyclase activity is also considered to be mediated by postsynaptic 5-HT1A receptors (16) . These observations suggest that pre-and postsynaptic 5-HT1A receptors differ in their functions. In this line, previous studies show that postsynaptic 5-HT1A receptors may be involved in the anticonflict/antidepressant effects of azapirones (17 -20) , although there are contradictory observations (21, 22) . In order to elucidate the mechanism for the pharmacology of 5-HT1A-receptor agonists, it appears to be important not only to discover potent and selective 5-HT1A receptor agonists but also to study how the ligands act on pre-and postsynaptic 5-HT1A receptors. In this paper, we examined the neurochemical profile of the new compound MKC-242 (Fig. 1) , which was developed as a 5-HT1A-receptor-related anxiolytic (23) . The present study demonstrates that MKC-242 acts as a full agonist at presynaptic 5-HT1A receptors and as a partial agonist at postsynaptic 5-HT1A receptors. Certain of these results were communicated to the Japanese Neurochemical Society (24) . 
MATERIALS AND METHODS

Animals
Male Wistar rats (Shimizu Lab. Supplies Co., Ltd., Kyoto) were maintained under controlled environmental conditions (22 ± 1 C ; 12-12 hr light-dark cycle, lights on at 8:00; food and water ad libitum) for at least 1 week before being used for the experiments.
In vitro radioligand binding studies
In general, the rats were killed by decapitation, and their hippocampi, striata and cerebral corticies were immediately dissected according to Glowinsky and Iversen (25) . The tissues were homogenized, and the membrane fractions were prepared for binding assays. The following assays were used (the description of each assay given in the following order: recognition site, [3H]ligand, the concentration, tissue, non-specific binding): Adenylate cyclase assay Rat hippocampi were homogenized in 20 volumes of 0.32 M sucrose, 1 mM EGTA, 5 mM EDTA, 5 mM dithiothreitol and 20 mM Tris-HC1 (pH 7.4) and then centrifuged at 39,000 x g for 10 min. The pellet was suspended in the homogenizing solution and used for the enzyme assay. Adenylate cyclase activity was determined according to the method of De Vivo and Maayani (16) , except that the amount of cAMP formed was measured by a radioimmunoassay with an assay kit (34) .
Determination of amines and their metabolites
The rats were killed by decapitation, and the samples for HPLC were prepared from their brain regions as previously reported (26) . Eicompak MA-SODS (4.6 x 150 mm) (Eicom, Kyoto) and Eicompak CA-SODS (4.6 x 150 mm) (Eicom) were used for 5-hydroxytryptophan (5-HTP), 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), dihydroxyphenylalanine (DOPA), DA and 3,4-dihydroxyphenylacetic acid (DOPAC) assays and for norepinephrine (NE) and 3-methoxy-4-hydroxyphenylglycol (MHPG) assays, respectively. The mobile phases were as follows: 15 mM sodium acetate-citrate buffer (pH 2.7) containing 150 mg/1 sodium 1-octanesulfonate, 15 uM EDTA and 12(v/v)% methanol for 5-HTP; 40 mM sodium acetatecitrate buffer (pH 3.5) containing 220 mg/1 sodium 1-octanesulfonate, 15 pM EDTA and 13 -17% methanol for 5-HT, 5-HIAA, DA and DOPAC; 95 mM sodium phosphate buffer (pH 6.0) containing 1.85 mM sodium 1-octanesulfonate, 134 pM EDTA and 5% methanol for NE and MHPG. Other conditions were reported previously (26) .
Microdialysis procedure
Rats (250-350g) were anesthetized with chloral hydrate (400 mg/kg, i.p.) and placed in a stereotaxic apparatus. A hole was drilled in the skull for implantation of a guide cannula (Eicom) according to Paxinos and Watson (35) . The guide was cemented to the skull along with an anchoring skull screw. The probe tip was positioned in the hypothalamus (AP -1.8, ML 0.7, DV -9 .5 relative to the bregma). After the rats recovered from surgery, the probe in which the active probe membrane was 2 mm was perfused at a constant flow rate of 2 p1/min with artificial cerebrospinal fluid (140 mM NaCI, 3.35 mM KCI, 1.15 mM MgC12, 1.26 mM CaC12, 1.20 mM Na2HPO4 and 0.30 mM NaH2PO4, pH 7.4) containing 1 uM citalopram, a 5-HT-uptake inhibitor. Every 20 min, perfusates were collected and immediately injected onto HPLC column with electrochemical detection for the 5-HT assay.
Determination of rectal temperature
Rats were habituated to a rectal probe (Baily Instrument, Clifton, NJ, USA) three times before the experiment was started. Body temperature was recorded with the rectal probe (inserted 2.5 cm).
Determination of serum corticosterone level
The serum corticosterone concentration was determined spectrofluorometrically by the method of Solem and Brinck-Johnsen (36).
Behavioral observations
The rats were pretreated with reserpine (1 mg/kg, s.c.) 18 hr before administration of 8-OH-DPAT and MKC-242. Observation sessions of 45 sec duration began 5 min later, and they were repeated every 3 min over a period of 12 min. The rats were observed by the procedure of Tricklebank et al. (37) and scored for individual components of the 5-HT behavioral syndrome (forepaw treading, lateral head weaving, hindlimb abduction and flat body posture) on a 4-point ranked intensity scale (0=ab-sent, 1= equivocal, 2 = present and 3 = intense). These values were summed for each rat over the 12-min observation period to give a maximum possible score of 15.
The palpebral aperture was evaluated by an experienced observer "blind" as to the treatment as reported by Millan et al. (38) . For the in vitro studies, MKC-242, its enantiomer, and racemate were dissolved in 0.02 M acetic acid to make a 5-mM solution, and subsequent dilutions were made in distilled water. For s.c. administration, they were suspended in 0.5% carboxymethylcellulose.
Data analyses
Tests of significance were made by one-way ANOVA followed by the Duncan and LSD multiple tests, with P values smaller than 0.05 being considered significant. Brain 5-HT and catecholamine turnover Table 2 decreased 5-HT turnover without changes in NE and DA turnover, while at 3.0 mg/kg, it decreased 5-HT turnover with concomitant increases in NE and DA turnover. An MKC-242-induced decrease in 5-HIAA/5-HT ratio was observed at 0.5 -2 hr after injection, and it disappeared by 4 hr (data not shown). Oral administration of MKC-242 showed a similar effect. MKC-242 decreased the 5-HIAA/5-HT ratio in all brain regions, although the degree of the decrease was smaller in the hippocampus and striatum than in the hypothalamus and cortex (data not shown). The effects of MKC-242 and 8-OH-DPAT on 5-HT turnover were compared by determining the 5-HTP accumulation induced by the decarboxylase inhibitor NSD-1015, another useful index of 5-HT turnover (Fig.  2) . Both compounds dose-dependently decreased 5-HTP accumulation in the hypothalamus, hippocampus and cortex; MKC-242 was less potent than 8-OH-DPAT, but there was no difference in the maximum effect (efficacy) between these compounds. The effect of MKC-242 on 5-HTP accumulation was attenuated by WAY100135, a 5-HT1A-receptor antagonist (Fig. 3) . Figure 4 shows the effect of MKC-242 on 5-HT release in the hypothalamus of a freely-moving rat. Administration of MKC-242 decreased the 5-HT release in a dosedependent manner.
5-HT release
Body temperature
Both MKC-242 and 8-OH-DPAT caused a dose-dependent decrease in rectal temperature, although the maximum decrease by MKC-242 was smaller than that by 8-OH-DPAT (Fig. 5A) . The hypothermic effect of MKC-242 at 0.5 mg/kg reached the maximum at 30 -60 min after injection and disappeared by 2 hr (data not shown).
The effect of MKC-242 on body temperature was attenuated by pretreatment with WAY100135 (Fig. 6 ).
Corticosterone secretion Injection of MKC-242 increased the serum corticosterone level, although the maximum effect by MKC-242 was smaller than that by 8-OH-DPAT (Fig. 5B) . The effect of MKC-242 at 0.5 mg/kg reached the maximum at 60 min after injection and disappeared by 2 hr (data not shown).
Behavioral studies
Administration of MKC-242 and 8-OH-DPAT to reserpine-treated rats elicited typical 5-HT-syndrome behaviors such as flat body posture, forepaw treading, hindlimb abduction and lateral headweaving (Fig. 7) . The maximum effect by MKC-242, which was observed at 2 -5 mg/kg, was smaller than that of 8-OH-DPAT. Subcutaneous injection of MKC-242 at 0.1-2 mg/kg did not elicit ptosis (data not shown).
Forskolin-stimulated adenylate cyclase MKC-242 and 8-OH-DPAT inhibited the activity of forskolin-stimulated adenylate cyclase in rat hippocampal membranes (Fig. 8) . The effects of these compounds were statistically significant, although the degree of inhibition was small (about 20%). The EC50 values for MKC-242 and 8-OH-DPAT were estimated to be approximately 3.5 nM and 15 nM, respectively. 
DISCUSSION
In vitro radioligand binding showed that MKC-242 had an extremely high affinity for 5-HT1A receptors (Table 1) . The interaction between MKC-242 and 5-HT1A receptors was stereospecific: MKC-242 ((S)-enantiomer) had 15-times higher affinity for the receptors than the (R)-enantiomer. The difference in the potency between these enantiomers was also observed in their hypothermic effect (data not shown). In tests of selectivity, MKC-242 showed low affinities for other 5-HT-receptor subtypes, 5-HT transporter and other neurotransmitter receptors except for a1-adrenoceptors. It is reported that some 5-HT1A-receptor ligands such as NAN-190, BMY 7378 and SDZ 216-525 (38-41) act as a1-adrenoceptor antagonists. In the separate experiments, we have observed that MKC-242 at 100 pM blocked the NE-induced increase in intracellular Ca2+ concentration in cultured rat astrocytes (data not shown). This in vitro result suggests that MKC-242 may be a weak a1-adrenoceptor antagonist. In contrast, the compound (0.1-2 mg/kg, s.c.) did not elicit ptosis (data not shown), an in vivo response to peripheral a1-adrenoceptor blockade (38) . Although it is not known if MKC-242 interacts with a1-adrenoceptors in the central nervous system in vivo, it is conceivable that the pharmacological effects of the compound result originally from the interaction with 5-HT1A-receptors, since the effects are completely blocked by the specific 5-HT1A-receptor antagonist WAY100135 (Figs. 3 and 6) .
5-HT1A receptors are present on the soma and dendrites of 5-HT neurons and on postsynaptic neurons in various regions of the limbic system (12). These 5-HT1A receptors exhibit different physiological characteristics as described in the Introduction.
The difference between pre-and postsynaptic 5-HT1A receptors is also reported in the sensitivities to drugs and pertussis and cholera toxins (42, 43) Therefore, information on pre-and postsynaptic 5-HT1A receptor mechanisms may contribute to a better understanding of the pharmacological effects of 5-HT1A-receptor agonists. The present study was performed to determine how MKC-242 affects these 5-HT1A receptors.
It is well-known that the decrease in 5-HT turnover is mediated by presynaptic 5-HT1A receptors (15) . Administration of MKC-242 decreased not only 5-HT turnover as determined by decreases in the 5-HIAA/5-HT ratio (Table 2 ) and the accumulation of 5-HTP (Fig. 2) , but also 5-HT release (Fig. 4) . The maximum effect of MKC-242 on 5-HT turnover was almost similar to that of 8-OH-DPAT, a full agonist of the receptors: there was no difference in the efficacies of these drugs. Furthermore, the effect of MKC-242 on the accumulation of 5-HTP was blocked by WAY100135 (Fig. 3) . These findings suggest that MKC-242 acts as a full agonist at presynaptic 5-HT1A receptors. The effect of MKC-242 on postsynaptic 5-HT1A receptors was examined in both in vitro and in vivo systems. MKC-242 partially inhibited forskolinstimulated adenylate cyclase activity (Fig. 8) . In contrast to the in vivo experiments, the experiment on adenylate cyclase inhibition did not show any significant difference in efficacy between MKC-242 and 8-OH-DPAT. In this assay system, it was difficult to make a distinction between a full agonist and a partial agonist, since the degree of inhibition by the full agonist 8-OH-DPAT was small. Administration of MKC-242 caused hypothermia (Fig.  5) , an increase in serum corticosterone level (Fig. 7) and 5-HT1A behavioral syndrome (Fig. 8) (50) . The present study shows that MKC-242 is ranked among the most potent 5-HT1A-receptor agonists. Most of these 5-HT1A-receptor agonists, unlike the azapirones (7), appear to be full agonists at postsynaptic 5-HT1A receptors, although they have not been fully characterized. MKC-242 is similar to FG5893
(48) and MDL 73005EF (38) with respect to their interaction with postsynaptic 5-HT1A receptors: they act as partial agonists at the postsynaptic sites. However, FG5893 is also a potent 5-HT2A receptor antagonist (48) and MDL 73005EF has lower affinity for 5-HT1A receptors than MKC-242 (51). Furthermore, it is noteworthy that MKC-242 contrasts with azapirones in the following respects: First, MKC-242 can not give rise to 1-(2-pyrimidyl) piperazine, a metabolite common to all the azapirones, which may reduce their therapeutic potential (11) . Second, MKC-242 at 0.3 -1.0 mg/kg does not affect DA turnover (Table 2) , whereas buspirone is reported to act as a DA D2 antagonist and to increase DA turnover (8, 52, 53) . Although MKC-242 at the high dose increases DA turnover (Table 2) , the effect does not appear to be related to the direct action on DA D2 receptors in view of the high selectivity of MKC-242 for 5-HT1A receptors versus DA D2 receptors. Taking these facts together, it is considered that MKC-242 is a novel compound with higher specificity for 5-HT1A receptors and characteristics as a partial agonist at postsynaptic 5-HT1A receptors.
In conclusion, MKC-242, a new compound, is a highly potent and selective 5-HT1A-receptor agonist, and it acts as a full agonist at presynaptic 5-HT1A receptors and a partial agonist at postsyanptic 5-HT1A receptors. It is considered that postsynaptic 5-HT1A receptors may be responsible for the anxiolytic and antidepressant effects of azapirones, partial 5-HT1A-receptor agonists (6, 7) . Therefore, the present study, together with the evidence that MKC-242 has anticonflict and antidepressant-like effects in animal models (23) , suggests that MKC-242 may be a useful research tool for exploring the functional roles of 5-HT1A receptors. Thus it is a promising candidate for clinical evaluation as a treatment for anxiety and depression. Using this compound, we have recently demonstrated that postsynaptic 5-HT1A receptors play a role in the anti-immobility effect of 5-HTIA-receptor agonists in the forced swimming test (54) , and the 5-HT1A receptors modulate NE release in the hypothalamus and hippocampus (55).
